ANEB ANEBULO PHARMACEUTICALS INC revenue, earnings and financials
For the quarter ended December 31, 2025, ANEBULO PHARMACEUTICALS INC reported revenue of n/a, net income of −$2.00M and diluted EPS of −$0.05; for the fiscal year ended June 2025 revenue was n/a.
ANEB annual revenue and earnings
- Fiscal year ended Jun 2025: revenue n/a, gross profit n/a, operating income −$9.22M, net income −$8.48M (margin n/a), EPS −$0.25
- Fiscal year ended Jun 2024: revenue n/a, gross profit n/a, operating income −$8.31M, net income −$8.20M (margin n/a), EPS −$0.32
- Fiscal year ended Jun 2023: revenue n/a, gross profit n/a, operating income −$11.8M, net income −$11.7M (margin n/a), EPS −$0.47
- Fiscal year ended Jun 2022: revenue n/a, gross profit n/a, operating income −$6.83M, net income −$6.83M (margin n/a), EPS $0.29
- Fiscal year ended Jun 2021: revenue n/a, gross profit n/a, operating income −$3.61M, net income −$30.3M (margin n/a), EPS −$2.83
ANEB quarterly revenue and earnings
- Quarter ended Dec 31, 2025: revenue n/a, net income −$2.00M, EPS −$0.05
- Quarter ended Sep 30, 2025: revenue n/a, net income −$2.16M, EPS −$0.05
- Quarter ended Jun 30, 2025 (from the annual report): revenue n/a, net income −$2.14M, EPS −$0.04
- Quarter ended Mar 31, 2025: revenue n/a, net income −$1.68M, EPS −$0.04
- Quarter ended Dec 31, 2024: revenue n/a, net income −$2.46M, EPS −$0.09
- Quarter ended Sep 30, 2024: revenue n/a, net income −$2.20M, EPS −$0.08
- Quarter ended Jun 30, 2024 (from the annual report): revenue n/a, net income −$1.35M, EPS −$0.05
- Quarter ended Mar 31, 2024: revenue n/a, net income −$1.65M, EPS −$0.06
- Quarter ended Dec 31, 2023: revenue n/a, net income −$2.72M, EPS −$0.11
- Quarter ended Sep 30, 2023: revenue n/a, net income −$2.48M, EPS −$0.10
- Quarter ended Jun 30, 2023 (from the annual report): revenue n/a, net income −$2.50M, EPS −$0.10
- Quarter ended Mar 31, 2023: revenue n/a, net income −$2.80M, EPS −$0.11
- Quarter ended Dec 31, 2022: revenue n/a, net income −$3.83M, EPS −$0.15
- Quarter ended Sep 30, 2022: revenue n/a, net income −$2.61M, EPS −$0.11
- Quarter ended Jun 30, 2022 (from the annual report): revenue n/a, net income −$2.32M, EPS n/a
- Quarter ended Mar 31, 2022: revenue n/a, net income −$1.88M, EPS n/a
- Quarter ended Dec 31, 2021: revenue n/a, net income −$1.07M, EPS −$0.05
- Quarter ended Sep 30, 2021: revenue n/a, net income −$1.55M, EPS −$0.07
- Quarter ended Mar 31, 2021: revenue n/a, net income −$556K, EPS −$0.68
ANEB cash flow, buybacks and dividends
- Fiscal year ended Jun 2025: operating cash flow −$6.35M, share buybacks n/a
- Fiscal year ended Jun 2024: operating cash flow −$8.09M, share buybacks n/a
- Fiscal year ended Jun 2023: operating cash flow −$9.68M, share buybacks n/a
- Fiscal year ended Jun 2022: operating cash flow −$5.44M, share buybacks n/a
- Fiscal year ended Jun 2021: operating cash flow −$4.87M, share buybacks n/a
ANEB balance sheet
- Dec 31, 2025: cash $9.04M, total assets $9.42M, total liabilities $1.49M, shareholders' equity $7.94M
- Sep 30, 2025: cash $10.4M, total assets $10.7M, total liabilities $964K, shareholders' equity $9.74M
- Jun 30, 2025: cash $11.6M, total assets $12.1M, total liabilities $488K, shareholders' equity $11.7M
- Mar 31, 2025: cash $13.3M, total assets $14.0M, total liabilities $546K, shareholders' equity $13.5M
- Dec 31, 2024: cash $15.0M, total assets $15.8M, total liabilities $879K, shareholders' equity $15.0M
- Sep 30, 2024: cash $1.40M, total assets $2.47M, total liabilities $569K, shareholders' equity $1.90M
- Jun 30, 2024: cash $3.09M, total assets $4.07M, total liabilities $261K, shareholders' equity $3.81M
- Mar 31, 2024: cash $5.15M, total assets $6.00M, total liabilities $1.01M, shareholders' equity $4.99M
Is ANEB profitable?
No. ANEBULO PHARMACEUTICALS INC lost $7.98M over the last four quarters.
What is ANEB's EPS?
Diluted earnings per share over the last four quarters were −$0.18; −$0.05 in the latest quarter.